scholarly journals Evolutions in the Management of Hepatocellular Carcinoma over Last 4 Decades: An Analysis from the 100 Most Influential Articles in the Field

Liver Cancer ◽  
2021 ◽  
pp. 1-14
Author(s):  
Gang Xu ◽  
Bao Jin ◽  
Xiaomeng Xian ◽  
Huayu Yang ◽  
Haitao Zhao ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Surgical Management ◽  
Checkpoint Inhibitors ◽  
Mainland China ◽  
Future Directions ◽  
Locoregional Treatment ◽  
The Past ◽  
The Usa ◽  
Number Of Publications ◽  
Specialist Field

<b><i>Introduction:</i></b> Over the past 4 decades, the management of hepatocellular carcinoma (HCC) has changed dramatically. The publications that have had the most significant impact on HCC management have not been quantitatively analyzed. In this article, we analyzed the 100 most influential articles over the past 4 decades using bibliometric citation analysis to characterize the evolution in HCC treatment. <b><i>Methods:</i></b> The top-cited publications were identified and analyzed from the Clarivate Analytics Web of Science Core Collection database. <b><i>Results:</i></b> The 100 most cited articles were identified with an average of 738 citations (range: 349–6,799). There was an increase in the number of influential articles in the late 1990s, which was paralleled by an increase in reports focused on locoregional treatment of HCC. Most top 100 articles came from the USA (<i>n</i> = 35), followed by Italy (<i>n</i> = 28), mainland China (<i>n</i> = 26), and Japan (<i>n</i> = 24). The surgical management was the most studied topic (<i>n</i> = 33). The <i>Annals of Surgery</i> published the highest number of papers (<i>n</i> = 26) with 13,978 citations. While other 3 topics (surgical management, locoregional treatment, and outcome prediction) declined among publications beginning in the 2000s, there was an emergence of highly cited papers on targeted drugs and immune checkpoint inhibitors with a concomitant increase in the number of publications on systemic therapy. <b><i>Conclusions:</i></b> Based on bibliometric analysis of the literature over the last 40 years, a comprehensive analysis of the most historically significant HCC management articles highlighted the key contributions made to the evolution and advancement of this specialist field. The data should provide clinicians and researchers insight into future directions relative to the advancement of HCC management.

International Publication Trends in Proteasome Inhibitors: From Tools for Cell Biologists to Anticancer Agents

2019 ◽  
Vol 16 (9) ◽  
pp. 1031-1039
Author(s):  
Peng Zhou ◽  
Minhui Zhu ◽  
Caiyun Zhang ◽  
Donghui Chen ◽  
Hongliang Zheng
Keyword(s):  
Anticancer Agents ◽  
Proteasome Inhibitors ◽  
Publication Trends ◽  
H Index ◽  
The Past ◽  
Dana Farber Cancer Institute ◽  
The Usa ◽  
The Subject ◽  
Number Of Publications ◽  
Scientific Fields

Background: There has been increased interest in the research of proteasome inhibitors for more than two decades. Hotspots in this field are constantly changing. Objective: This study aimed to investigate trends in proteasome inhibitors research from 1992 to 2018 and compare the contributions of such research from different countries and authors. Methods: We used Excel 2013 and VoSviewer to analyze bibliometric data on the subject of proteasome inhibitors, including the number of publications, citations frequency, H-index, and country contributions and hotspots (keywords of popular scientific fields). Results: A total of 3646 articles were included. The USA contributed the largest percentage of articles (1742), with the most citations (90666) and the highest H-index (139). The journal Blood had the most articles. Dana Farber Cancer Institute and Millennium Pharmaceuticals Incorporation were the most contributive institutions. Keywords could be divided into three clusters: Basic experiment, clinical research, and others. Conclusion: The number of proteasome inhibitors articles has been increasing for the past 27 years. The USA made the largest contribution in this field. Recent studies on the topic of “carfilzomib” are relatively new and should be closely followed in proteasome inhibitors research.

Systemic Therapy for Hepatocellular Carcinoma: Advances and Hopes

2020 ◽  
Vol 20 (2) ◽  
pp. 84-99
Author(s):  
Chen-Hao Zhang ◽  
Ming Li ◽  
You-Pei Lin ◽  
Qiang Gao
Keyword(s):  
Hepatocellular Carcinoma ◽  
Systemic Therapy ◽  
Checkpoint Inhibitors ◽  
Statistical Significance ◽  
Progression Free Survival ◽  
Second Line ◽  
Future Directions ◽  
Free Survival ◽  
First Line Therapy ◽  
Systemic Treatments

The majority of patients with hepatocellular carcinoma (HCC) are diagnosed at an advanced stage that can only benefit from systemic treatments. Although HCC is highly treatmentresistant, significant achievements have been made in the molecular targeted therapy and immunotherapy of HCC. In addition to regorafenib, cabozantinib and ramucirumab were approved for the second- line targeted treatment by the FDA after disease progression on sorafenib. Nivolumab failed to demonstrate remarkable benefit in overall survival (OS) as first-line therapy, while pembrolizumab did not achieve pre-specified statistical significance in both OS and progression-free survival (PFS) as second-line treatment. Combinations of targeted agents, immune checkpoint inhibitors and other interventions showed favorable results. In this review, we summarized the progress of systemic therapy in HCC and discussed the future directions of the treatment of HCC.

scholarly journals Therapy of Intermediate-Stage Hepatocellular Carcinoma: Current Evidence and Clinical Practice

2020 ◽  
Vol 37 (05) ◽  
pp. 456-465
Author(s):  
Nathan X. Chai ◽  
Julius Chapiro
Keyword(s):  
Hepatocellular Carcinoma ◽  
Thermal Ablation ◽  
Clinical Evidence ◽  
Checkpoint Inhibitors ◽  
Intermediate Stage ◽  
Locoregional Therapy ◽  
Current Evidence ◽  
Locoregional Treatment ◽  
Wide Range ◽  
Bland Embolization

AbstractIntermediate-stage Hepatocellular Carcinoma (HCC) represents a wide range of disease burden. Patients with different levels of liver function, tumor size, and number of lesions may all have intermediate-stage disease according to the Barcelona Clinic Liver Cancer (BCLC) staging system. Several minimally invasive image-guided locoregional therapies are available for the treatment of intermediate-stage HCC, including conventional transarterial chemoembolization (cTACE), drug-eluting bead TACE (DEB-TACE), yttrium-90 radioembolization (Y-90 RE), thermal ablation, bland embolization, and combination therapy. Available clinical evidence points to cTACE as the current gold standard for the locoregional treatment of intermediate-stage HCC. DEB-TACE is at best non-inferior to cTACE in terms of survival benefit. Y-90 RE is a maturing therapy, and some institutions have adopted it as first-line therapy for intermediate-stage HCC. Thermal ablation combined with TACE may be used in select patients, while bland embolization has only limited evidence for its use. The combination of locoregional therapy with VEGF inhibitors or immune checkpoint inhibitors has also been explored. This article will examine in detail the clinical evidence supporting available locoregional treatment options for intermediate-stage HCC.

scholarly journals Global Research Trends on Prostate Diseases and Erectile Dysfunction: A Bibliometric and Visualized Study

2021 ◽  
Vol 10 ◽  
Author(s):  
Chengquan Ma ◽  
Hao Su ◽  
Hongjun Li
Keyword(s):  
Erectile Dysfunction ◽  
Future Research ◽  
Comprehensive Overview ◽  
The Past ◽  
Software Network ◽  
The Usa ◽  
Future Research Directions ◽  
Number Of Publications ◽  
Prostate Diseases

ObjectivesTo identify the cooperation of authors, countries, institutions and explore the hot topics’ prospects regarding research of prostate diseases and erectile dysfunction (ED).MethodsPublications on research of prostate diseases and ED were retrieved from the Web of Science Core Collection (WoSCC). Bibliometric analyses were performed using VOSviewer and CiteSpace software. Network maps were generated to evaluate the collaborations between different authors, countries, institutions, and keywords.ResultsA total of 2,599 articles related to study of prostate diseases and ED were identified. We observed gradually increasing in the number of publications from 1998 to 2016, and the trend was to be relatively stable in the past 3 years. Journal of Sexual Medicine (243 papers) owned the highest number of publications and Journal of Urology was the most co-cited journal. Mulhall John P (52 papers) was the top most productive authors and Mcvary Kebin T with the largest numbers of citations (1,589 co-citations) during the past decades. There were active collaborations among the top authors. The USA was the leading contributor in this field with 1,078 papers. Active cooperation between countries and between institutions was observed. The main hot topics included matters related to erectile dysfunction, prostate cancer, quality-of-life, radical prostatectomy, sexual function, and BPH.ConclusionBibliometric analysis provides a comprehensive overview of the development of scientific literature, allowing relevant authors and research teams to recognize the current research status in this field and at the same time provide a reference for formulating future research directions.

scholarly journals Lessons From Immune Checkpoint Inhibitor Trials in Hepatocellular Carcinoma

2021 ◽  
Vol 12 ◽  
Author(s):  
Raphael Mohr ◽  
Fabian Jost-Brinkmann ◽  
Burcin Özdirik ◽  
Joeri Lambrecht ◽  
Linda Hammerich ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Immune Checkpoint ◽  
Kinase Inhibitors ◽  
Checkpoint Inhibitor ◽  
Checkpoint Inhibitors ◽  
Standard Of Care ◽  
Durable Response ◽  
Future Directions ◽  
Proven Efficacy ◽  
Line Setting

The implementation of immune checkpoint inhibitors (ICI) into the clinical management of different malignancies has largely changed our understanding of cancer treatment. After having proven efficacy in different tumor entities such as malignant melanoma and lung cancer, ICI were intensively tested in the setting of hepatocellular carcinoma (HCC). Here they could achieve higher and more durable response rates compared to tyrosine-kinase inhibitors (TKI), that were sole standard of care for the last decade. Most recently, ICI treatment was approved in a first line setting of HCC, for cases not suitable for curative strategies. However, only a subset of patients benefits from ICI therapy, while others experience rapid tumor progression, worsening of liver function and poor prognosis. Efforts are being made to find immune characteristics that predict tumor responsiveness to ICI, but no reliable biomarker could be identified so far. Nevertheless, data convincingly demonstrate that combination therapies (such as dual inhibition of PD-L1 and VEGF) are more effective than the application of single agents. In this review, we will briefly recapitulate the current algorithms for systemic treatment, discuss available results from checkpoint inhibitor trials and give an outlook on future directions of immunotherapy in HCC.

scholarly journals Immunotherapy for hepatocellular carcinoma: current status and future perspectives

ESMO Open ◽  
2018 ◽  
Vol 3 (Suppl 1) ◽  
pp. e000455 ◽  
Author(s):  
Takuji Okusaka ◽  
Masafumi Ikeda
Keyword(s):  
Hepatocellular Carcinoma ◽  
Immune Checkpoint ◽  
Immune Checkpoint Inhibitors ◽  
Standard Treatment ◽  
Checkpoint Inhibitors ◽  
Local Therapy ◽  
Current Status ◽  
Therapeutic Drug ◽  
Future Perspectives ◽  
The Usa

The discovery of the immune checkpoint mechanism has contributed greatly to recent advances in cancer treatment. The anticytotoxic T lymphocyte-associated protein 4 antibody ipilimumab was first approved as a therapeutic drug for malignant melanoma in the USA in 2011; since then, antiprogrammed cell death 1 (PD-1) antibody and antiprogrammed death-ligand 1 (PD-L1) antibody have also been approved and clinically introduced and are indicated for the treatment of various cancers. Numerous clinical studies are now underway to evaluate the efficacy of immune checkpoint inhibitors for patients with many kinds of cancer, including hepatocellular carcinoma (HCC), and the outcomes of these trials are highly anticipated. Synergic effects of immune checkpoint inhibitors used in combination with molecular targeted agents or local therapy have also been suggested, resulting in expectations regarding the use of these drugs in combination with existing standard treatment methods for HCC. Thus, the treatment of HCC is now entering an age of significant innovation triggered by the clinical introduction of immune checkpoint inhibitors.

Intracerebral Hemorrhage

2018 ◽  
pp. 37-44
Author(s):  
Opeolu Adeoye
Keyword(s):  
Blood Pressure ◽  
Clinical Trials ◽  
Intracerebral Hemorrhage ◽  
Surgical Management ◽  
Clinical Management ◽  
Intraventricular Hemorrhage ◽  
Severe Form ◽  
Spontaneous Intracerebral Hemorrhage ◽  
Future Directions ◽  
The Past

Spontaneous intracerebral hemorrhage (ICH) is a severe form of stroke with no proven treatments to date. However, multiple clinical trials in the past decade have contributed to the growing knowledge in the field, and ongoing trials will further inform clinical management. Completed and ongoing trials have informed blood pressure management, surgical management, hemostasis, treatment of coagulopathy, treatment of intraventricular hemorrhage, and neuroprotection, among others. This chapter discusses recent advancements in ICH, how those advancements have informed clinical management, and future directions for innovative research that may lead to proven interventions for ICH.

On Future Directions in Pathology

1982 ◽  
Vol 40 ◽  
pp. 274-277
Author(s):  
Benjamin F. Trump ◽  
Irene K. Berezesky ◽  
Raymond T. Jones
Keyword(s):  
Electron Microscopy ◽  
Transmission Electron Microscopy ◽  
Clinical Pathology ◽  
Future Directions ◽  
Diagnostic Pathology ◽  
The Past ◽  
Transmission Electron ◽  
Organ Systems ◽  
The Many

The role of electron microscopy and associated techniques is assured in diagnostic pathology. At the present time, most of the progress has been made on tissues examined by transmission electron microscopy (TEM) and correlated with light microscopy (LM) and by cytochemistry using both plastic and paraffin-embedded materials. As mentioned elsewhere in this symposium, this has revolutionized many fields of pathology including diagnostic, anatomic and clinical pathology. It began with the kidney; however, it has now been extended to most other organ systems and to tumor diagnosis in general. The results of the past few years tend to indicate the future directions and needs of this expanding field. Now, in addition to routine EM, pathologists have access to the many newly developed methods and instruments mentioned below which should aid considerably not only in diagnostic pathology but in investigative pathology as well.

Cross-culture outcomes of a brazilian professor Fulbright in the USA

2017 ◽  
Vol 26 (50) ◽  
pp. 115
Author(s):  
Marcelo Da Silva Leite ◽  
Celeste Gaia
Keyword(s):  
Higher Education ◽  
Low Cost ◽  
Cross Culture ◽  
College And University ◽  
Governmental Agencies ◽  
The Past ◽  
University Curriculum ◽  
Fulbright Scholar ◽  
The Usa ◽  
Higher Education Costs

Over the past decade due the expansion of globalization there has been an increasing emphasis on internationalization among faculty, administration and accrediting agencies in the Higher Education.  Although to promote internationalization in the Higher Education, costs are a big challenge, one way to have the international actions with low cost, it is seeking for grants from different governmental agencies and foundations.The Fulbright Scholar program provides a long-standing and externally-funded means for internationalizing college and university curriculum. This article is going to share the perspective   of a Brazilian Fulbright Scholar at an American college and the institution perspective of the Fulbright scholar participation at the College.

Sign in / Sign up

Export Citation Format

Share Document